Imagine if you could ask questions about studies across the field of HIV vaccines

What would you want to know?

That's what we'll be asking members at the CAVD annual meeting (Dec 6-8) in Seattle.

We've been hearing questions like ...

• How predictive are NHP studies?
• What’s the longevity of responses in one species vs another?
• How did the same regimen used in my study do in pre-clinical studies?
• What's produced better breadth of antibody neutralization: vaccines with gp140 (trimeric) or vaccines with gp120 (monomeric) portions of Env?
• If macaques tend to have better responses then humans, what's different about those human volunteers that have responses similar to what we see in macaques?

Stop by the demo station and tell us what you'd like to know. Let DataSpace help you find the answers.